Literature DB >> 12734647

Endothelin receptor blockade in canine oleic acid-induced lung injury.

Ives Hubloue1, Dominique Biarent1, Sophia Abdel Kafi1, Gilbert Bejjani1, Christian Mélot1, Robert Naeije1, Marc Leeman2,3.   

Abstract

OBJECTIVE: To investigate the effects of endogenous endothelins on pulmonary haemodynamics and gas exchange in oleic acid lung injury.
DESIGN: Prospective experimental study in dogs.
SETTING: Animal research laboratory in a university teaching hospital. SUBJECTS. Seventeen anaesthetised and ventilated mongrel dogs.
INTERVENTIONS: Nine pretreated dogs received an infusion of the endothelin A and B receptor antagonist bosentan (10 mg/kg) started before oleic acid. Eight treated dogs received bosentan started 90 min after oleic acid. Cardiac index (CI) was manipulated by inflating an inferior vena caval balloon or by opening a femoral arterio-venous bypass. MEASUREMENTS AND
RESULTS: Pulmonary vascular resistance was defined by measuring the gradient between mean pulmonary artery pressure (MPAP) and occluded PAP (PAOP) at five levels of CI. Intrapulmonary shunt was measured using the inert gas SF(6). Pretreatment with bosentan prevented the oleic acid-induced shift of (MPAP-PAOP)/CI plots to higher pressures, but did not affect the increase in intrapulmonary shunt. Treatment of established oleic acid lung injury with bosentan had no effect.
CONCLUSIONS: Pretreatment, but not treatment, with bosentan, in the dose used, blunted the oleic acid-induced increase in pulmonary vascular resistance, suggesting that endothelins contribute to the increase in pulmonary vascular tone in the early stages of oleic acid lung injury.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734647     DOI: 10.1007/s00134-003-1683-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  16 in total

1.  Pulmonary vasoregulation by endothelin in conscious dogs after left lung transplantation.

Authors:  S Doi; N Smedira; P A Murray
Journal:  J Appl Physiol (1985)       Date:  2000-01

Review 2.  Endothelins and the lung.

Authors:  J R Michael; B A Markewitz
Journal:  Am J Respir Crit Care Med       Date:  1996-09       Impact factor: 21.405

3.  Inert gas elimination characteristics of the normal and abnormal lung.

Authors:  M P Hlastala; H T Robertson
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1978-02

4.  Nature of pulmonary hypertension in canine oleic acid pulmonary edema.

Authors:  M Leeman; P Lejeune; J Closset; J L Vachiéry; C Mélot; R Naeije
Journal:  J Appl Physiol (1985)       Date:  1990-07

Review 5.  ARDS: clinical lessons from the oleic acid model of acute lung injury.

Authors:  D P Schuster
Journal:  Am J Respir Crit Care Med       Date:  1994-01       Impact factor: 21.405

6.  Influence of cardiac output on intrapulmonary shunt.

Authors:  J P Lynch; J G Mhyre; D R Dantzker
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1979-02

7.  Release of endothelin in the oleic acid-induced respiratory distress syndrome in rats.

Authors:  T Simmet; S Pritze; K I Thelen; B A Peskar
Journal:  Eur J Pharmacol       Date:  1992-02-18       Impact factor: 4.432

8.  Inhaled endothelin A antagonist improves arterial oxygenation in experimental acute lung injury.

Authors:  U Kaisers; T Busch; S Wolf; H Lohbrunner; K Wilkens; B Hocher; W Boemke
Journal:  Intensive Care Med       Date:  2000-09       Impact factor: 17.440

9.  Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.

Authors:  M Clozel; V Breu; G A Gray; B Kalina; B M Löffler; K Burri; J M Cassal; G Hirth; M Müller; W Neidhart
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

10.  Endothelin-1 does not mediate hypoxic vasoconstriction in canine isolated blood vessels: effect of BQ-123.

Authors:  S A Douglas; L M Vickery-Clark; E H Ohlstein
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

View more
  7 in total

Review 1.  Year in review in intensive care medicine-2003. Part 3: intensive care unit organization, scoring, quality of life, ethics, neonatal and pediatrics, and experimental.

Authors:  Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoit Vallet
Journal:  Intensive Care Med       Date:  2004-06-26       Impact factor: 17.440

2.  Preparation and anesthetic properties of propofol microemulsions in rats.

Authors:  Timothy E Morey; Jerome H Modell; Dushyant Shekhawat; Todd Grand; Dinesh O Shah; Nikolaus Gravenstein; Susan P McGorray; Donn M Dennis
Journal:  Anesthesiology       Date:  2006-06       Impact factor: 7.892

Review 3.  Pathophysiology of pulmonary hypertension in acute lung injury.

Authors:  Laura C Price; Danny F McAuley; Philip S Marino; Simon J Finney; Mark J Griffiths; Stephen John Wort
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-13       Impact factor: 5.464

Review 4.  Current Pharmacological Approach to ARDS: The Place of Bosentan.

Authors:  Omer Araz
Journal:  Eurasian J Med       Date:  2020-02

5.  Endothelin-1 impairs alveolar epithelial function via endothelial ETB receptor.

Authors:  Alejandro P Comellas; Arturo Briva; Laura A Dada; Maria L Butti; Humberto E Trejo; Cecilia Yshii; Zaher S Azzam; Juan Litvan; Jiwang Chen; Emilia Lecuona; Liuska M Pesce; Masashi Yanagisawa; Jacob I Sznajder
Journal:  Am J Respir Crit Care Med       Date:  2008-10-23       Impact factor: 21.405

6.  In vitro identification and in silico utilization of interspecies sequence similarities using GeneChip technology.

Authors:  Dmitry N Grigoryev; Shwu-Fan Ma; Brett A Simon; Rafael A Irizarry; Shui Q Ye; Joe G N Garcia
Journal:  BMC Genomics       Date:  2005-05-04       Impact factor: 3.969

7.  Endothelin antagonists: new bullets against lung injury?

Authors:  Marc Leeman
Journal:  Crit Care       Date:  2005-04-14       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.